Llibre JM, Lopez Cortes LF, Aylott A, Wynne B, et al. Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2. J Acquir Immune Defic Syndr 2022;91:73-78.
PMID: 35551149